skip to main | skip to sidebar

HEALTH ECONOMICS BLOG - Trends, Politics, Opinions etc. in biotech & pharma industry

Health Economics and HTA and its role in pricing and reimbursement, pipeline and in-lisencing evaluations as well as portfolio and company valuations in the biotech and pharmaceutical sector is ever increasing. While I was searching the web for various news on the topic, I actually couldn't find a blog that offers a platform of exchange among professionals in this field around the various topics - so there we go now and I hope you enjoy the information... Cheers Ulf

1.22.2008

Best Practices in Global Oncology Clinical Trials - free event

Prologue is hosting a free event on Best Practices in Global Oncology Clinical Trials. More details on marketwire.
Posted by ustaginnus@hotmail.com at 1/22/2008

No comments:

Post a Comment

Newer Post Older Post Home
Subscribe to: Post Comments (Atom)

Blog Archive

  • ►  2007 (29)
    • November (18)
    • December (11)
  • ▼  2008 (75)
    • January (14)
    • February (7)
    • March (10)
    • April (6)
    • May (4)
    • June (3)
    • July (7)
    • August (3)
    • September (4)
    • October (9)
    • November (5)
    • December (3)
  • ►  2009 (41)
    • January (8)
    • February (4)
    • March (4)
    • April (4)
    • May (1)
    • June (5)
    • July (2)
    • August (3)
    • September (3)
    • October (2)
    • November (2)
    • December (3)
  • ►  2010 (31)
    • January (1)
    • February (8)
    • March (2)
    • May (2)
    • June (2)
    • July (3)
    • August (2)
    • September (4)
    • October (3)
    • November (2)
    • December (2)
  • ►  2011 (29)
    • January (6)
    • February (3)
    • March (1)
    • May (2)
    • June (4)
    • July (3)
    • August (2)
    • September (4)
    • October (3)
    • November (1)
  • ►  2012 (16)
    • January (1)
    • February (4)
    • May (3)
    • July (2)
    • August (1)
    • October (1)
    • November (1)
    • December (3)
  • ►  2013 (13)
    • January (2)
    • February (3)
    • March (2)
    • April (1)
    • May (1)
    • June (1)
    • September (1)
    • November (1)
    • December (1)
  • ►  2014 (5)
    • February (1)
    • May (2)
    • July (1)
    • October (1)
  • ►  2015 (4)
    • March (1)
    • June (1)
    • July (1)
    • November (1)
  • ►  2016 (3)
    • April (1)
    • August (1)
    • October (1)
  • ►  2017 (1)
    • May (1)

Followers

Search the blog

Subscribe to my blog via email

Enter your email address:

Delivered by FeedBurner

 Subscribe in a reader

about the author

Ulf Staginnus is a health economist with more than 15 years of international experience in health economics, pricing and market access strategies as well as competitive intelligence and health technology valuations. He is a regular speaker on pricing and health economics related matters and contributed to various articles and authored book chapters on strategy and tactics of pharmaceutical pricing and health economics. Ulf also adviced pharma, biotech and medical device companies as well as health care investors on business prospects, investment opportunities and product pricing, health outcomes as well as market access strategies.

Upcoming events

Fleming Europe

8TH ANNUAL
PRICING, REIMBURSEMENT & MARKET ACCESS



January 17th/18th 2013

Barcelona, Spain

Biotech Investing, Funds, Venture capital

  • BB Biotech

Economics

  • National Bureau of Economic Research
  • The Economist
  • EconLib

links related to health economics, biotechnology and competitive intelligence

  • http://www.biospace.com
  • http://www.biotechblog.com
  • http://www.healtheconomics.com
  • http://www.htablog.com
  • http://www.pharmamarketingblog.com
  • International Society for Pharmacoeconomics and Outcomes Research
  • Pharma CI Conference & Exhibition
  • Society for Competitive Intelligence Professionals
  • Spanish Journal of Health Economics

HTA agencies

  • http://www.infarmed.pt
  • http://www.iqwig.de
  • http://www.lfn.se
  • http://www.nice.org.uk
 
Add to Technorati Favorites